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Abstract
Extended thromboprophylaxis with oral anticoagulation can reduce the risk of symptomatic venous thromboembolism (VTE) in
high-risk patients. We sought to estimate the proportion of medically ill patients in the United States who might qualify for
extended thromboprophylaxis according to the criteria used in the Medically-Ill Patient Assessment of Rivaroxaban versus
Placebo in Reducing Post-Discharge Venous ThromboEmbolism Risk (MARINER) trial. We analyzed 2014 National Inpatient
Sample (NIS) data that provide a 20% weighted annual sample of all discharges from US acute-care hospitals. Hospitalizations for
acute medically ill patients were identified as those with a primary discharge diagnosis code for heart or respiratory failure,
ischemic stroke, infection, or inflammatory diseases. Patients were excluded if they were <40 years old, admitted for surgery or
trauma, had a length of stay <3- or >35-days, or were contraindicated to nonvitamin K antagonist oral anticoagulants. The
modified International Medical Prevention Registry on Venous Thromboembolism (IMPROVE)-VTE score was used to stratify
patients’ risk for postdischarge VTE, with a score of 2 to 3 suggesting patients were at moderate- and 4 as high-risk. Of the
35 358 810 hospitalizations in the 2014 NIS, 1 849 535 were medically ill patients admitted for heart failure (10.1%), respiratory
failure (12.2%), ischemic stroke (8.8%), infection (58.5%), or inflammatory diseases (10.4%). The modified IMPROVE-VTE score
classified 1 186 475 (64.1%) of these hospitalizations as occurring in moderate-risk and 407 095 (22.0%) in high-risk patients. This
real-world study suggests a substantial proportion of acute medically ill patients might benefit from extended thromboprophylaxis
using the modified IMPROVE-VTE score and clinical elements of the MARINER trial.
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Introduction
Patients with an acute medical illness such as pneumonia,
stroke, or congestive heart failure are highly susceptible to the
development of venous thromboembolism (VTE) during their
hospital stay and up to 3-months postdischarge.1,2 Randomized
controlled trials (RCTs).3-6suggest that high-risk medically ill
patients can reduce their risk of symptomatic VTE by initiating
thromboprophylaxis in-hospital and continuing extended
thromboprophylaxis for up to 6 weeks postdischarge but at the
potential cost of additional bleeding.7 The trials randomized
acute medically ill patients 40 years of age but used different
strategies to target high-risk populations, such as D-dimers and
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risk scores. At present, it is unclear what proportion of medi-
cally ill patients warrant extended thromboprophylaxis. A bet-
ter understanding of the proportion and characteristics of
medically ill patients who may qualify for extended thrombo-
prophylaxis will allow health care decision makers to better
understand the potential costs/expenditure needed to provide
such an intervention as well as to estimate potential down-
stream costs savings from preventing VTE. Therefore, we
sought estimate the proportion of hospitalizations in medically
ill patients in the United States that might qualify for extended
thromboprophylaxis according to clinical criteria used in the
Medically Ill Patient Assessment of Rivaroxaban versus Pla-
cebo in Reducing Post-Discharge Venous ThromboEmbolism
Risk (MARINER) trial for identifying an at-VTE risk group.5
Methods
This study utilized the 2014 Agency for Healthcare Research
and Quality Healthcare Cost and Utilization Project National
Inpatient Sample (NIS).8 The NIS is among the largest pub-
lically available inpatient databases in the United States and
approximates a 20% sample of discharges from hospitals across
the country. National Inpatient Sample covers Medicare,
Medicaid, privately insured, and uninsured patients, and con-
tains data on patient and hospital demographics and billing
codes (up to 30 International Classification of Diseases-
Ninth Revision (ICD-9) diagnosis, 15 ICD-9 procedural codes
and corresponding Clinical Classifications Software [CCS]
diagnosis, and procedure code groupings) per encounter. No
laboratory or medication utilization data are available in the
NIS, including availability of D-dimer testing. The 2014 inpa-
tient core file contains data on 35 358 810 hospitalizations
occurring between January 1, 2014, and December 31, 2014,
drawn from 4411 hospitals across 44 states.
This analysis defined candidacy for extended thrombopro-
phylaxis as being a medically ill patient at sufficient risk accord-
ing to the criteria utilized in the MARINER trial (which
evaluated rivaroxaban vs placebo for extended thromboprophy-
laxis).5 The MARINER trial criteria were chosen (vs other RCT
criteria) due to greater ease of implementation in an administra-
tive claims database. All eligibility criteria were identified using
provided demographics or ICD-9 diagnosis, procedural or CCS-
based coding. Eligibility criteria included a hospitalization for a
medically ill patient 40 years of age with a primary billing
code for decompensated heart failure, respiratory failure, infec-
tion, ischemic stroke, or inflammatory disease (including rheu-
matic diseases), survival to discharge, and a duration of
hospitalization  3 but 35 days.3-5 Hospitalizations for major
surgical procedures, occurring in patients with a comorbidity
requiring full-dose anticoagulation (eg, admission for VTE, his-
tory of atrial fibrillation or heart valve replacement) or with a
prior history of clinically-relevant bleeding, trauma, or injury or
a contraindication to a nonvitamin k oral anticoagulant (NOAC;
eg, coagulopathy, liver disease, alcohol abuse, acquired immu-
nodeficiency syndrome, sustained uncontrolled hypertension, or
severe renal insufficiency) were excluded from this analysis.
Hospitalizations for medically ill patients meeting the above-
mentioned criteria were further risk stratified using the modified
International Medical Prevention Registry on Venous Throm-
boembolism (IMPROVE) score to be consistent with the MAR-
INER study design.5,9 The modified IMPROVE risk score uses
age (60 years), complete immobilization or sedentary with or
without bathroom privileges for 1 day (assumed present in
everyone for this study), prior VTE, history of cancer, thrombo-
philia or lower limb paralysis, as well as the need for an intensive
or critical care unit stay (hospitalization coded for sepsis, respira-
tory, or acute decompensated heart failure) to assess patients’
risk of subsequent VTE (area under the curve¼ 0.72).10 Patients
with a score 4 were deemed high risk, 2 to 3 at moderate risk,
and 1 at low risk of VTE up to 3 months after admission. The
modified IMPROVE score differs from the original in its defi-
nition of immobility (immobilization lasting for 1 day vs 7
days) and the inclusion of patients with either active or a prior
history of cancer versus a history of cancer only. A sensitivity
analysis in which we applied the original IMPROVE score
immobility criteria of 7 days (also the approximate mean
length of stay in the MARINER trial population)5 was
performed.
Categorical data were reported as percentages, while con-
tinuous data were summarized as medians with 25%, 75%
ranges. All data management was performed using IBM SPSS
Statistics version 25.0 (IBM Corp, Armonk, New York). As
this analysis was only performed on data that were deidentified
and in compliance with the Health Insurance Portability and
Accountability Act of 1996 to preserve participant anonymity
and confidentiality, it was deemed exempt from institutional
review board oversight.
Results and Discussion
In total, 35 358 810 hospital discharges were captured in the
2014 NIS data set (Figure 1). We excluded 10 492 770 (29.7%),
10 490 660 (29.7%), and 8 419 555 (23.8%) hospitalizations
because patients were less than 40 years of age, lacked the
required medical conditions, or had a primary code for a sur-
gical procedure, respectively. We then excluded 1 395 875
(3.9%), 1 177 065 (3.3%), 979 170 (2.8%), and 548 180
(1.6%) hospitalizations because patients were ineligible for
extended thromboprophylaxis due to the need for full-dose
anticoagulation, high-risk of bleeding, hospital length of stay
<3 or >35 days, or ending in death or had a likely contraindica-
tion to NOAC use, respectively.
This left 1 849 535 discharges for patients with an acute
medical illness meeting initial MARINER criteria (Table 1). The
most frequent reasons for admission included acute infection
(58.5%), respiratory failure (12.2%), and heart failure (10.1%).
Upon risk stratification, 407 095 (22.0%) were calculated as
having a modified IMPROVE score 4 (high-risk), 1 186 475
(64.2%) a score of 2 to 3 (moderate-risk), and the remaining 255
965 (13.8%) having a score of 1 or less (low-risk).
Our study provides a real-world estimate of the proportion
of hospitalizations in the United States associated with patients
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who might qualify for extended thromboprophylaxis. Unlike
randomized trials3-5 that are performed in select centers and
only include patients who agree to be studied, the utilized NIS
data set8 had millions of hospitalizations and data are likely
more representative of the US population. We found that 22.0%
of hospitalized acute medically ill patients in the 2014 NIS data
set are at high risk of VTE according to the modified
IMPROVE VTE score from the MARINER trial criteria,5,9 and
thus might benefit from extended thromboprophylaxis after
discharge. Another 64.2% of hospitalized acute medically ill
patients were found to be at moderate risk, requiring D-dimer
testing to determine their suitability for extended thrombopro-
phylaxis.5 Compared to the IMPROVE registry10 which found
7% of medical inpatients to have a score of 4 (high-risk; and
25% a score of 2-3 [moderate-risk]), our study indicated a
larger proportion of medically ill patients (22%) may be at high
risk of VTE. The reason for the greater proportion of high-risk
patients identified in our study versus the IMPROVE registry
may be a result of our use of age40 and not 18 years of age as
in IMPROVE registry and our defining immobility as
Figure 1. Flow of study inclusion and exclusion. IMPROVE, indicates International Medical Prevention Registry on Venous Thromboembolism;
LOS, length-of-stay; N, number of hospitalizations; NOAC, nonvitamin k oral anticoagulant.
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a duration of hospital stay 1-day as opposed to the 7-day
value used in the IMPROVE registry. Importantly, both age
and immobilization risk were risk factors assigned a point in
the modified IMPROVE score. Moreover, the additional inclu-
sion of an elevated D-dimer level as a risk factor for moderate-
risk patients makes direct comparison of our results to that of
the IMPROVE registry difficult.
There are 4 main trials supporting the benefit of extended
thromboprophylaxis with NOACs in patients hospitalized with
an acute medical illness. The Apixaban Dosing to Optimize
Protection from Thrombosis (ADOPT) trial6 randomized acute
medically ill patients (n ¼ 6528) 40 years of age who had
restricted mobility and additional risk factors (such as previous
VTE, cancer, or obesity) to apixaban 2.5 mg twice daily for
30 days or enoxaparin 40 mg once daily for at least 6 days
while in the hospital. Apixaban did not significantly reduce the
primary composite end point of VTE-related death, pulmonary
embolism (PE), and symptomatic or asymptomatic VTE
detected through ultrasonography (2.71% vs 3.06%; relative
risk, 0.87; 95% confidence interval [CI] ¼ 0.62-1.23; P ¼
.44). The Multicenter, Randomized, Parallel Group Efficacy
and Safety Study for the Prevention of Venous Thromboembo-
lism in Hospitalized Acutely Ill Medical Patients Comparing
Rivaroxaban with Enoxaparin (MAGELLAN) trial3 rando-
mized patients (n ¼ 8101) 40 years of age who were
hospitalized for an acute medical illness to rivaroxaban 10
mg once daily for 35+ 4 days or enoxaparin 40 mg once daily
for 10 + 4 days. At day 35, the rivaroxaban group showed a
significant reduction in the primary composite outcome of total
VTE and VTE-related death (4.4% vs 5.7%; relative risk, 0.77;
95% CI ¼ 0.62-0.96; P ¼ .02). Medically-Ill Patient Assess-
ment of Rivaroxaban versus Placebo in Reducing Post-
Discharge Venous ThromboEmbolism Risk5 randomized
medically ill patients (n ¼ 12 019) 40 years of age who were
at an increased risk for VTE (identified using D-dimer and the
IMPROVE VTE risk stratification tool) to rivaroxaban 10 mg
once daily or placebo for 45-days postdischarge. The rivarox-
aban group insignificantly reduced the primary composite out-
come of symptomatic VTE and VTE-related death versus
placebo (0.83% vs 1.10%; hazard ratio, 0.76; 95%CI ¼ 0.52-
1.09; P¼ .14) while significantly decreasing patients hazard of
symptomatic VTE events alone compared to placebo (0.18% vs
0.42%; hazard ratio, 0.44; 95%CI ¼ 0.22-0.89). Medically-Ill
Patient Assessment of Rivaroxaban versus Placebo in Reduc-
ing Post-Discharge Venous ThromboEmbolism Risk employed
an overly broad definition of VTE-related death, including
sudden deaths in which PE could not be ruled out in the primary
composite outcome. The Acute Medically Ill VTE Prevention
with Extended Duration Betrixaban (APEX) trial4 randomized
medically ill patients (n ¼ 7513) 40 years of age who were at
Table 1. Characteristics of Hospitalizations in the 2014 National Inpatient Sample, Stratified by Thrombosis Risk.
All, n (%) Low-Risk, n (%) Moderate-Risk, n (%) High-Risk, n (%)
Number of discharges 1 849 535 255 965 1 186 475 407 095
Demographics
Age, years (median, 25%, 75% range) 70 (58, 81) 51 (46, 55) 72 (62, 83) 73 (64, 83)
Female sex 1 081 935 (58.5%) 149 875 (58.6%) 708 640 (59.7%) 223 420 (54.9%)
Length of stay, days (median, 25%, 75% range) 4 (3, 6) 4 (3, 5) 4 (3, 6) 5 (3, 7)
Race
White 1 268 520 (68.6%) 165 675 (64.7%) 808 455 (68.1%) 294 390 (72.3%)
African American 264 585 (14.3%) 43 135 (16.9%) 168 410 (14.2%) 53 040 (13.0%)
Hispanic 148 445 (8.0%) 26 465 (10.3%) 97 140 (8.2%) 24 840 (6.1%)
Asian or Pacific Islander 36 710 (2.0%) 3050 (1.2%) 26 645 (2.2%) 7015 (1.7%)
Native American 10 205 (0.6%) 1865 (0.7%) 6750 (0.6%) 1590 (0.4%)
Other 43 740 (2.4%) 6875 (2.7%) 28 495 (2.4%) 8370 (2.1%)
Missing 77 330 (4.2%) 8900 (3.5%) 50 580 (4.3%) 17 850 (4.4%)
Qualifying primary medical diagnosis
Heart failure 186 530 (10.1%) 145 (0.1%) 152 160 (12.8%) 34 225 (8.4%)
Respiratory failure 225 110 (12.2%) 56 810 (22.2%) 133 030 (11.2%) 35 270 (8.7%)
Infection 1 081 805 (58.5%) 148 075 (57.8%) 667 575 (56.3%) 266 155 (65.4%)
Ischemic stroke 162 445 (8.8%) 0 (0%) 132 440 (11.2%) 30 005 (7.4%)
Inflammatory/rheumatic disorder 193 645 (10.4%) 50 935 (19.9%) 101 270 (8.5%) 41 440 (10.1%)
Modified IMPROVE VTE risk factorsa
History of VTE (3 points) 110 875 (6.0%) - 0 (0%) 110 875 (27.2%)
Thrombophilia (2 points) 7535 (0.4%) - 790 (0.1%) 6745 (1.7%)
Cancer (2 points) 336 855 (18.2%) - 30 800 (2.6%) 306 055 (75.2%)
Lower limb paralysis (2 points) 28 980 (1.6%) - 5685 (0.5%) 23 295 (5.7%)
ICU/CCU stay (1 point) 901 390 (48.7%) - 679 510 (57.3%) 221 880 (54.5%)
Age 60 years (1 point) 1 318 610 (71.3%) - 975 395 (82.2%) 343 215 (84.3%)
Abbreviations: CCU, critical care unit; ICU, intensive care unit; IMPROVE, International Medical Prevention Registry on Venous Thromboembolism; VTE, venous
thromboembolism.
aValue in () represent points assigned in the modified IMPROVE score.
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an increased risk of VTE (identified using D-dimer and advan-
cing age) to betrixaban 80 mg once daily for 35 to 42 days or
enoxaparin 40 mg once daily for 10+ 4 days. Betrixaban did
not significantly reduce the primary end point of total VTE and
VTE-related death in the primary population but significantly
reduced the primary end point in the overall population (4.4%
vs 6.0%; relative risk, 0.75; 95%CI ¼ 0.61-0.91; P ¼ .003).
Based on the APEX data, betrixaban is currently the only Food
and Drug Administration–approved NOAC for prolonged
thromboprophylaxis in medically ill patients.11
The criteria used for determining the need for
extended thromboprophylaxis is relatively similar across the
MAGELLAN,3 APEX,4 MARINER,5 and ADOPT6 trials.
Each used an age 40 years, presence of acute medical illness,
and tested a duration of NOAC therapy ranging from 35 to
45 days. Each trial3-5 used an acute medical illness definition
consisting of heart failure, respiratory failure, acute infection,
inflammatory/rheumatic disorder, and acute ischemic stroke.
Certain exclusion criteria present in MARINER, such as active
cancer, cardiogenic or septic shock requiring vasopressor sup-
port, severe bronchiectasis, and cavitary tuberculosis, were not
applied in this study because they were used as a risk factor in
the modified IMPROVE score, not consistently utilized as
exclusion criteria in other RCTs of extended duration throm-
boprophylaxis or amounted to an insignificant portion of the
population (<0.1%). All 3 trials also included similar added
VTE risk factors including the presence of advanced age, his-
tory of VTE, cancer (active or history of), thrombophilia, as
well as immobility criteria. We utilized the MARINER5 cri-
teria using the IMPROVE VTE score9 in our study, as it was
the most amendable to implementation in claims data. How-
ever, the MARINER criteria5 and the APEX criteria4 for
extended thromboprophylaxis required data on D-dimer levels
(2x the upper limit of normal), which are not available in
claims data sets such as the NIS.8 Based on modified
IMPROVE VTE scores,9 we were able to identify a high-risk
subpopulation that should receive extended thromboprophy-
laxis per the clinical criteria in MARINER5 and a subpopula-
tion that was at low-risk and should not be offered therapy
regardless of their D-dimer values (and so levels should not
be ordered). We also identified a substantial population at mod-
erate risk of VTE that would require D-dimer concentrations to
discern their suitability for extended thromboprophylaxis.
Given continued thromboprophylaxis may increase clinically
relevant bleeding risk, D-dimer testing is warranted in this
subpopulation. Of note, 47.6% of the study population in
MAGELLEN3,12 had elevated D-dimer concentrations  twice
the upper limit of normal, while in the MARINER trial,5 70.4%
of patients had the same threshold of an elevated D-dimer.
Unfortunately, it is unclear if the presence of an elevated
D-dimer meeting threshold criterion was evenly distributed
across the various risk categories in these trials.3-5 Thus, we
estimate that at least 22% of all hospitalized acute medically ill
patients in our sample might have qualified from extended
thromboprophylaxis based on clinical criteria alone.
Our study has several additional limitations worth noting.
First, biases such as misclassification can negatively impact the
internal validity of claims database analyses.13 Second, NIS
does not contain robust data on immobility,8 and there are
typically substantial issues in the evaluation of immobility sta-
tus in clinical studies (including interobserver variability in
severity assessment and a lack of standardized definitions). The
MAGELLAN3 and APEX4 trials defined immobility as being
confined to a bed or chair for the majority of the day, with
independent mobility only to the in-room toilet for at least
24-hours. The MARINER trial5 used current lower limb
paralysis or paresis, which is defined as a leg falling to the bed
within 5 seconds but with the limb able to impart effort against
gravity. In our study, all patients with a hospital length of stay
for  3 days were considered immobile. Of note, our use of
hospitalization for  3 days as a surrogate for immobility in
this study may have resulted in an overestimation of patient
risk. To address this concern, we performed a sensitivity anal-
ysis raising the cutoff to  7-days which resulted in 14.6% (as
compared to 22% in the base case) of hospitalized acute medi-
cally ill patients being classified as high risk and 43.2% (com-
pared to 64.2%) at moderate risk. However, we believe our a
priori definition of immobility (more consistent with the mod-
ified IMPROVE score) is more likely to be accurate, as stud-
ies suggest immobility tends to be front loaded (occurring in
the first 24-48 hours) of a hospital admission.14 Finally, we
used NIS data so that our conclusion may be less general-
izable to non-US populations with acute medical illness
requiring hospitalization.8,12
Conclusion
This real-world study suggests that there is a substantial
population of acute medically ill patients who would
benefit from extended thromboprophylaxis using the modi-
fied IMPROVE VTE score and clinical elements of the
MARINER trial criteria.
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